Getinge AB (publ) (GNGBF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNGBF representa a Getinge AB (publ), una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 50/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Getinge AB (publ) (GNGBF) Resumen de Asistencia Médica y Tuberías
Getinge AB (publ) is a global provider of medical technology, offering solutions for operating rooms, intensive care units, and sterilization departments. With a diverse portfolio spanning acute care, life science, and surgical workflows, Getinge serves healthcare providers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, maintaining a significant presence in the medical device industry.
Tesis de Inversión
Getinge AB (publ) presents a compelling investment case based on its established market position and diverse product portfolio within the healthcare sector. With a current P/E ratio of 22.79 and a dividend yield of 2.43%, the company demonstrates financial stability. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. The company's focus on acute care therapies, life science solutions, and surgical workflows positions it to capitalize on increasing healthcare spending and technological advancements. However, potential risks include regulatory hurdles and competition from other medical device manufacturers. The company's gross margin of 45.9% and profit margin of 6.5% indicate a solid foundation for future growth.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $5.90B reflects Getinge's significant presence in the medical device industry.
- P/E Ratio of 22.79 indicates a valuation in line with industry peers.
- Gross Margin of 45.9% demonstrates efficient cost management and pricing strategies.
- Dividend Yield of 2.43% provides a steady return for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Strong global presence and distribution network.
- Diverse product portfolio across multiple healthcare segments.
- Established brand reputation and customer loyalty.
- Focus on innovation and technological advancements.
Debilidades
- Exposure to regulatory risks and compliance requirements.
- Dependence on healthcare spending and economic conditions.
- Competition from larger medical device manufacturers.
- Potential for product recalls and liability claims.
Catalizadores
- Ongoing: Expansion of product portfolio through research and development.
- Ongoing: Increasing demand for healthcare solutions in emerging markets.
- Ongoing: Strategic partnerships and acquisitions to expand market reach.
- Upcoming: Potential regulatory approvals for new medical devices.
- Upcoming: Launch of innovative surgical workflow solutions in Q4 2026.
Riesgos
- Potential: Changes in healthcare regulations and reimbursement policies.
- Potential: Economic downturns and reduced healthcare spending.
- Ongoing: Increasing competition from established and emerging players.
- Potential: Product recalls and liability claims.
- Ongoing: Fluctuations in currency exchange rates.
Oportunidades de crecimiento
- Growth opportunity 1: Expansion in Emerging Markets: Getinge has the opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where healthcare spending is rapidly increasing. By tailoring its product offerings to meet the specific needs of these markets, Getinge can capitalize on the growing demand for advanced medical technologies. This expansion could contribute significantly to revenue growth over the next 3-5 years, with the global medical device market projected to reach $600 billion by 2025.
- Growth opportunity 2: Innovation in Surgical Workflows: Getinge can further enhance its surgical workflow solutions by integrating advanced technologies such as robotics and artificial intelligence. This would improve the efficiency and precision of surgical procedures, leading to better patient outcomes and increased demand for Getinge's products. The market for surgical robotics is expected to reach $12.6 billion by 2025, presenting a substantial growth opportunity for Getinge.
- Growth opportunity 3: Focus on Infection Control Solutions: With increasing concerns about hospital-acquired infections, Getinge can capitalize on the growing demand for advanced infection control solutions. By developing innovative sterilization and disinfection technologies, Getinge can help healthcare providers reduce the risk of infections and improve patient safety. The global infection control market is projected to reach $25 billion by 2027, offering a significant growth opportunity for Getinge.
- Growth opportunity 4: Strengthening the Life Science Segment: Getinge's Life Science segment can benefit from the increasing demand for bioprocessing solutions in the pharmaceutical and biotechnology industries. By expanding its portfolio of bioreactors, bioprocess control systems, and bioprocess software, Getinge can support the development and manufacturing of new drugs and therapies. The global bioprocessing market is expected to reach $35 billion by 2028, presenting a substantial growth opportunity for Getinge.
- Growth opportunity 5: Strategic Acquisitions and Partnerships: Getinge can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or entering into partnerships with leading healthcare providers, Getinge can strengthen its competitive position and accelerate its growth. This strategy can provide access to new markets and technologies, enhancing Getinge's long-term growth prospects.
Oportunidades
- Expansion in emerging markets with growing healthcare demand.
- Development of new products and solutions to address unmet needs.
- Strategic acquisitions and partnerships to expand market reach.
- Integration of advanced technologies such as AI and robotics.
Amenazas
- Increasing competition from established and emerging players.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
- Disruptive technologies and new market entrants.
Ventajas competitivas
- Established brand reputation in the medical device industry.
- Diverse product portfolio across multiple healthcare segments.
- Global distribution network providing access to a wide customer base.
- Strong focus on innovation and technological advancements.
Acerca de GNGBF
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a leading global provider of medical technology. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products and solutions for intensive care units, including advanced monitoring systems, anesthesia machines, and mechanical ventilation products. The Life Science segment provides solutions for sterile transfer, bioprocess control, and sterilization within the pharmaceutical and biotechnology industries. The Surgical Workflows segment focuses on optimizing operating room efficiency with products such as operating tables, surgical lights, and integrated OR management systems. Getinge's comprehensive portfolio includes sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems. The company also offers practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, and a range of surgical solutions. Getinge distributes its products through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, serving a global customer base.
Qué hacen
- Provides equipment for operating rooms.
- Offers solutions for intensive-care units.
- Supplies sterilization departments with necessary equipment.
- Develops and markets sterile transfer systems.
- Creates bioprocess control systems for the life science industry.
- Offers surgical assist systems and related solutions.
- Provides solutions for vascular and cardiothoracic surgery.
Modelo de Negocio
- Develops and manufactures medical devices and equipment.
- Sells products directly through proprietary sales companies.
- Utilizes agents and distributors for broader market reach.
- Provides after-sales service and support for its products.
Contexto de la Industria
Getinge AB (publ) operates within the global medical device industry, a sector characterized by continuous innovation and increasing demand driven by an aging population and rising healthcare expenditures. The industry is highly competitive, with key players focusing on technological advancements and geographic expansion. Getinge's focus on acute care therapies, life science solutions, and surgical workflows aligns with major market trends, including the growing demand for minimally invasive surgical procedures and advanced sterilization technologies. The company's global presence allows it to capitalize on growth opportunities in both developed and emerging markets.
Clientes Clave
- Hospitals and healthcare facilities.
- Pharmaceutical and biotechnology companies.
- Research institutions.
- Sterilization departments.
Finanzas
Gráfico e información
Precio de la acción de Getinge AB (publ) (GNGBF): Price data unavailable
Últimas noticias
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GNGBF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GNGBF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GNGBF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Últimas Noticias
Liderazgo: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). His career includes leadership roles in various technology and healthcare companies. He has a strong background in strategic management and business development. Prior to joining Getinge, Perjos held key positions at Coesia Group and Sandvik, gaining experience in international business and operational excellence. His expertise spans across multiple industries, providing him with a diverse perspective on business challenges and opportunities.
Historial: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business segments and expanding its global presence. He has overseen the implementation of strategic initiatives aimed at improving operational efficiency and driving innovation. Key achievements include the launch of new products and solutions, as well as the expansion of Getinge's service offerings. Perjos has also emphasized sustainability and corporate responsibility, aligning Getinge's business practices with environmental and social goals.
Información del mercado OTC de GNGBF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Getinge AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet higher listing standards. Investors should exercise significant caution when considering investments in OTC Other securities due to the increased risks associated with limited information and potential for fraud or manipulation.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Financial Disclosure: The lack of readily available and reliable financial information increases the risk of investing in GNGBF.
- Low Liquidity: The low trading volume and wide bid-ask spread can make it difficult to buy or sell shares at a fair price.
- Potential for Fraud or Manipulation: The OTC market is more susceptible to fraudulent schemes and market manipulation due to the lower regulatory oversight.
- Delisting Risk: GNGBF could be delisted from the OTC market if it fails to meet the minimum listing requirements or comply with regulatory standards.
- Information Asymmetry: The limited information available to investors can create an uneven playing field, where insiders have an advantage over outside investors.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's filings with regulatory agencies.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Check for any legal or regulatory actions against the company.
- Established Operations: Getinge AB (publ) has been in operation since 1904, indicating a long-standing presence in the medical device industry.
- Global Presence: The company has a global distribution network and serves customers in multiple regions.
- Diverse Product Portfolio: Getinge offers a wide range of products and solutions across various healthcare segments.
- Publicly Traded: While traded on the OTC market, the company is a publicly traded entity, subject to some level of regulatory oversight.
Preguntas Comunes Sobre GNGBF
¿Cuáles son los factores clave para evaluar GNGBF?
Getinge AB (publ) (GNGBF) actualmente tiene una puntuación IA de 50/100, indicando puntuación moderada. Fortaleza clave: Strong global presence and distribution network.. Riesgo principal a monitorear: Potential: Changes in healthcare regulations and reimbursement policies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GNGBF?
GNGBF actualmente puntúa 50/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GNGBF?
Los precios de GNGBF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GNGBF?
La cobertura de analistas para GNGBF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GNGBF?
Las categorías de riesgo para GNGBF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Changes in healthcare regulations and reimbursement policies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GNGBF?
La relación P/E para GNGBF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GNGBF sobrevalorada o infravalorada?
Determinar si Getinge AB (publ) (GNGBF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GNGBF?
Getinge AB (publ) (GNGBF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- AI analysis pending may provide further insights.
- OTC market data may have limited accuracy.